Get the latest news, insights, and market updates on BBNX (Beta Bionics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen’s 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabio Feb 19, 2026 - $BBNX
Beta Bionics Q4 Earnings Call Highlights
Beta Bionics (NASDAQ:BBNX) reported fourth-quarter and full-year 2025 results on its earnings call Tuesday, highlighting rapid user growth, expanding pharmacy reimbursement, and progress on its product pipeline while also addressing an FDA warning letter tied to quality-system observations. Full-ye Feb 18, 2026 - $BBNX
Beta Bionics (BBNX) Q4 2025 Earnings Transcript
Sean T. Saint: and I want to take a brief moment to reflect on it before we dive into the details of our Q4 and full year 2025 performance. Beta Bionics, Inc. exists to deliver solutions to people with diabetes that reduce burden, expand access, and ultimately improve outcomes at the population level. Feb 17, 2026 - $BBNX
Beta Bionics, Inc. (BBNX) Reports Q4 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) delivered earnings and revenue surprises of +28.57% and +0.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 17, 2026 - $BBNX
Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment Feb 17, 2026 - $BBNX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple